Sofia, Bulgaria has been selected to carry out the clinical trials and Amsterdam, the Netherlands for its analytical work. The trial requires consent of the European Regulatory bodies (EMEA) and must abide by all rules and regulations of drug approval within the EU Communities of countries.
"The data from these trials will cement the basis for a multinational clinical trials including United States under the FDA guideline, said Dr. Hassan Salari, Global Health President and CEO."
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
About Global Health Ventures
The Company is a specialty pharma focused on the life style products. The Company is developing a new proprietary platform technology that delivers many approved drugs via the sublingual (under the tongue) route. This unique method delivers low dose drugs directly to the blood stream, bypassing all the side effects of digestive and liver system breakdowns, while maintaining product efficacy.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
